JW (Cayman) Therapeutics Co. Ltd
JW Therapeutics is a Shanghai-based, Hong Kong-listed (HKEX: 2126) cell-immunotherapy company. Its CAR-T therapy relmacabtagene autoleucel (relma-cel, Carteyva) is approved in China.
| Headquarters | Shanghai, China |
|---|---|
| Listing | HKEX:02126 |
| Lead asset / stage | relmacabtagene autoleucel (relma-cel; Carteyva) Approved — China |
| Latest event | JW Therapeutics announced NMPA approval of a post-marketing manufacturing variation for Carteyva. |